Zoetis Inc. (ZTS) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $76.68. The rating moved from Oversold to Overbought on August 19, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$76.68
• Last changeMoved from Oversold to Overbought on August 19, 2026
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic

See all overbought Healthcare stocks →

AI analysis

Zoetis Inc. combines a durable, diversified animal-health franchise with steady cash generation and a defensive demand profile. Market position, recurring revenue from companion-animal products, and a growing diagnostics/biologics footprint support near-term resilience and moderate upside. Key catalysts include continued product innovation, targeted M&A, and margin expansion from operational efficiencies. Principal concerns are regulatory or safety setbacks, competition from lower-cost alternatives, and cyclical weakness in livestock end-markets that could compress growth or margins.

Key factors

• Leading global animal-health franchise with strong market share across companion animal and livestock segments
• Diversified product portfolio (vaccines, parasiticides, diagnostics, medicines) providing resilient revenues and pricing power
• Consistent cash flow generation and margin profile versus cyclical pharma peers; history of shareholder returns and M&A to supplement organic growth
• R&D pipeline and incremental biologics/diagnostics investments that can drive medium-term premium growth
• Defensive demand profile: veterinary services and pet ownership trends support steady end-market volume
• Limited immediate macro headline risk in the four-hour window; sector rotation favors defensive names

Risks

• Regulatory or safety setbacks for key products (veterinary approvals, adverse-event issues) that could pressure sales or require recalls
• Competitive pressure from generics, biosimilars, or new entrants in high-margin categories
• Agricultural commodity or livestock demand shocks that reduce farm animal drug volumes and pricing
• Currency volatility and emerging-market exposure that can weigh on reported results
• Execution risk on R&D programs, pipeline readouts, or integration of acquisitions
• Supply chain or manufacturing disruptions (including specialized biologics supply) that could hit margins and availability
• Broader macro weakness or reduced veterinary visit trends that slow growth

Latest MarketMoodz coverage

• Texas Screwworm Case Lifts Zoetis, Sparks Options Surge2026-06-04
• Burry Buys Beaten Stocks, Warns of AI-Fueled Dot-Com Echo2026-05-19
• Cisco Hits RSI 90 — Most Overbought S&P 500 Stock2026-05-16

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.